uniQure's post-royalty-sale revenue base remains volatile and insufficient to offset a heavy R&D cost structure, with TTM revenue down 40.6% and quarterly operating losses consistently between -$39M and -$56M.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.88+3.9% vs -$0.92 | $5M-15.9% vs $6M |
Q3 2026 Jul 29, 2026 | -$1.22-48.4% vs -$0.82 | $6M+7.2% vs $5M |
Q2 2026 May 5, 2026 | -$0.85+3.4% vs -$0.88 | $4M-31.6% vs $5M |
Q2 2026 Mar 2, 2026 | -$0.56+39.8% vs -$0.93 | $6M+4.5% vs $5M |
uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a target action date of May 1, 2027. The U.K. Medicines and Healthcare products Regulatory Agency has also validated the company's Marketing Authorization Application, according to management.
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~
Benchmark QURE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for uniQure N.V. (QURE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.70 | $1.51B | -6.51 | -40.64% | -1154.84% | -96.34% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — |
uniQure N.V. (QURE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
uniQure N.V. (QURE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 24, 2026·SEC
Jun 22, 2026·SEC
Get notified when QURE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
uniQure N.V. (QURE) stock FAQ — growth, dividends, profitability & financials explained
uniQure N.V. (QURE) reported $20.2M in revenue over the trailing twelve months. Revenue was $16.1M in fiscal year 2025.
uniQure N.V. (QURE) grew revenue by 28.0% over the trailing twelve months, compared with the twelve months before.
No. uniQure N.V. (QURE) reported a net loss of $232.9M over the trailing twelve months.
uniQure N.V. (QURE) had a return on equity (ROE) of -96.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
uniQure N.V. (QURE) had negative free cash flow of $178.0M in fiscal year 2025.
